The research team found that by blocking Galectin-9 and Tim-3 (immune-checkpoint molecules expressed on T cells and myeloid cells in adult and pediatric glioma TMEs) signaling, led to a reduction of M2 polarization and subsequent impairment in tumor progression (52–54). The gene discussed is HAVCR2; the disease is glioma.